Literature DB >> 27699996

Evaluating the Usefulness of Compulsory Licensing in Developing Countries: A Comparative Study of Thai and Brazilian Experiences Regarding Access to Aids Treatments.

Samira Guennif.   

Abstract

While compulsory licensing (CL) is described in the TRIPS agreement as flexibility to protect public health by improving access to medicines in developing countries, a recent literature contends adversely that CL may harm public health. Therefore, this article intends to evaluate the usefulness of CL in the South through the prism of obligations and goals entrusted to patent holders (the effective and non-abusive exploitation of patents in order to achieve industrial and health developments) and in light of experiences in Thailand and Brazil regarding access to antiretroviral drugs. In this way, it shows that the obligations assigned to patent holders were better served by the recipients of CL and brought significant health and industrial benefits in the two high middle-income countries. In particular, CL allowed the scaling-up of free and universal access to antiretroviral drugs by assuring the financial sustainability of these public health programs endangered by monopolistic practices from patent holders.
© 2016 John Wiley & Sons Ltd.

Keywords:  Drug accessibility; HIV/AIDS; compulsory licensing; developing countries; intellectual property rights; public health

Mesh:

Substances:

Year:  2016        PMID: 27699996     DOI: 10.1111/dewb.12124

Source DB:  PubMed          Journal:  Dev World Bioeth        ISSN: 1471-8731            Impact factor:   2.294


  2 in total

1.  Compulsory Licensing of Pharmaceuticals in High-Income Countries: A Comparative Analysis.

Authors:  Lindor Qunaj; Anna Kaltenboeck; Peter B Bach
Journal:  Milbank Q       Date:  2022-03-07       Impact factor: 6.237

2.  The Legislative Approach and System Improvement of China's Compulsory Licensing for Drug Patents.

Authors:  Zhang Cao; Yichao Chen; Wenjie Jiang; Wei Li
Journal:  Drug Des Devel Ther       Date:  2021-09-01       Impact factor: 4.162

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.